Switching from Aflibercept to Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration: Short-Term Results from Real-Life Study
Abstract
1. Introduction
2. Material and Methods
- Persistent subretinal fluid (SRF), intraretinal fluid (IRF), or pigment epithelial detachment (PED).
- Subretinal hemorrhage or subretinal hyperreflective material (SHRM) persistent after injection.
- No improvement in best-corrected visual acuity (BCVA).
- Inability to extend the treatment interval beyond four weeks.
Statistical Procedures
3. Results
3.1. Best-Corrected Visual Acuity (BCVA)
3.2. Central Subfoveal Retinal Thickness (CST)
4. Discussion
5. Study Limitations
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Ashraf, M.; Banaee, T.; Silva, F.Q.; Singh, R.P. Switching anti-vascular endothelial growth factors in refractory neovascular age-related macular degeneration. Ophthalmic Surg. Lasers Imaging Retin. 2018, 49, 166–170. [Google Scholar] [CrossRef]
- Gasperini, J.L.; Fawzi, A.A.; Khondkaryan, A.; Lam, L.; Chong, L.P.; Eliott, D.; Walsh, A.C.; Hwang, J.; Sadda, S.R. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br. J. Ophthalmol. 2011, 96, 14–20. [Google Scholar] [CrossRef] [PubMed]
- Airody, A.; Baseler, H.A.; Seymour, J.; Allgar, V.; Mukherjee, R.; Downey, L.; Dhar-Munshi, S.; Mahmood, S.; Balaskas, K.; Empeslidis, T.; et al. Treatment of age-related macular degeneration with aflibercept using a treat, extend and fixed protocol: A 4-year study of treatment outcomes, durability, safety and quality of life (An extension to the MATE randomised controlled trial). Acta Ophthalmol. 2023, 102, e328–e338. [Google Scholar] [CrossRef]
- Iglicki, M.; González, D.P.; Loewenstein, A.; Zur, D. Longer-acting treatments for neovascular age-related macular degeneration: Present and future. Eye 2021, 35, 1111–1116. [Google Scholar] [CrossRef]
- Cardoso, P.N.; Pinheiro, A.F.; Meira, J.; Pedrosa, A.C.; Falcão, M.S.; Pinheiro-Costa, J.; Falcão-Reis, F.; Carneiro, Â.M. Switch to aflibercept in the treatment of neovascular AMD: Long-term results. J. Ophthalmol. 2017, 2017, 6835782. [Google Scholar] [CrossRef]
- Pinheiro-Costa, J.; Costa, J.M.; Beato, J.N.; Freitas-Da-Costa, P.; Brandão, E.; Falcão, M.S.; Falcão-Reis, F.; Carneiro, Â.M. Switch to aflibercept in the treatment of neovascular AMD: One-year results in clinical practice. Ophthalmologica 2015, 233, 155–161. [Google Scholar] [CrossRef] [PubMed]
- European Medicines Agency. Vabysmo: EPAR—Product information [Internet]. Amsterdam: EMA; 2022 Oct. 13 [Updated 2025 Jul. 14; Cited 2025 Aug.]. Available online: https://www.ema.europa.eu/en/documents/product-information/vabysmo-epar-product-information_en.pdf (accessed on 8 October 2025).
- Spaide, R.F.; Jaffe, G.J.; Sarraf, D.; Freund, K.B.; Sadda, S.R.; Staurenghi, G.; Waheed, N.K.; Chakravarthy, U.; Rosenfeld, P.J.; Holz, F.G.; et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology 2020, 127, 616–636. [Google Scholar] [CrossRef] [PubMed]
- Chan, H.H.; Feo, A.; Cabral, D.; Bousquet, E.; Popovic, M.M.; Marin, A.I.; Quarta, A.; El-Haig, W.M.; Teo, K.Y.C.; Tan, A.C.S.; et al. Type 4 macular neovascularization (NV): A new member of the optical coherence tomography (OCT) classification of NV age-related macular degeneration (AMD). Retina, 2025; ahead of print. [Google Scholar] [CrossRef]
- Cheung, C.M.G.; Lai, T.Y.; Teo, K.; Ruamviboonsuk, P.; Chen, S.-J.; Kim, J.E.; Gomi, F.; Koh, A.H.; Kokame, G.; Jordan-Yu, J.M.; et al. Polypoidal Choroidal Vasculopathy: Consensus Nomenclature and Non-Indocyanine Green Angiograph Diagnostic Criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup. Ophthalmology 2021, 128, 443–452. [Google Scholar] [CrossRef] [PubMed]
- Waldstein, S.M.; Philip, A.-M.; Leitner, R.; Simader, C.; Langs, G.; Gerendas, B.S.; Schmidt-Erfurth, U. Correlation of 3-dimensionally quantified intraretinal and subretinal fluid with visual acuity in neovascular age-related macular degeneration. JAMA Ophthalmol. 2016, 134, 182–190. [Google Scholar] [CrossRef]
- Steinle, N.C.; McCullough, A.J.; Silva, F.Q.; Du, W.; Moini, H.; Singh, R.P. Impact of duration of exposure to intraretinal fluid on visual outcomes in neovascular age-related macular degeneration. Ophthalmol. Retin. 2024, 9, 618–624. [Google Scholar] [CrossRef]
- Chaudhary, V.M.; Matonti, F.; Zarranz-Ventura, J.M.; Stewart, M.W. Impact of fluid compartments on functional outcomes for patients with neovascular age-related macular degeneration: A systematic literature review. Retina 2021, 42, 589–606. [Google Scholar] [CrossRef]
- Llorente-González, S.; Hernandez, M.; González-Zamora, J.; Bilbao-Malavé, V.; Fernández-Robredo, P.; Saenz-De-Viteri, M.; Barrio-Barrio, J.; Rodríguez-Cid, M.J.; Donate, J.; Ascaso, F.J.; et al. The role of retinal fluid location in atrophy and fibrosis evolution of patients with neovascular age-related macular degeneration long-term treated in real world. Acta Ophthalmol. 2021, 100, e521–e531. [Google Scholar] [CrossRef]
- Foss, A.J.E.; Almeida, D.; Cheung, C.M.G.; Ogura, Y.; de Cock, E.; Empeslidis, T. To treat or not to treat? Resolving the question of subretinal and intraretinal fluid in age-related macular degeneration: A narrative review. Ophthalmol. Ther. 2025, 14, 489–514. [Google Scholar] [CrossRef]
- Sadda, S.; Holekamp, N.M.; Sarraf, D.; Ebraheem, A.; Fan, W.; Hill, L.; Blotner, S.; Spicer, G.; Gune, S. Relationship between retinal fluid characteristics and vision in neovascular age-related macular degeneration: HARBOR post hoc analysis. Graefe Arch. Clin. Exp. Ophthalmol. 2022, 260, 3781–3789. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, V.; Puzo, M.; Sanchez-Monroy, J.; Gabrielle, P.-H.; Garcher, C.C.; Baudin, F.; Wolff, B.; Castelnovo, L.; Michel, G.; O’TOole, L.; et al. Association between anatomical and clinical outcomes of neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor. Retina 2020, 41, 1446–1454. [Google Scholar] [CrossRef]
- Sánchez-Monroy, J.; Nguyen, V.; Puzo, M.; Calvo, P.; Arruabarrena, C.; Monaco, P.; Chilov, M.; Keegan, D.; Barthelmes, D.; Gillies, M. Subretinal fluid may protect against macular atrophy in neovascular age-related macular degeneration: 5 years of follow-up from Fight Retinal Blindness registry. Acta Ophthalmol. 2022, 101, 457–464. [Google Scholar] [CrossRef]
- Eckardt, F.; Lorger, A.; Hafner, M.; Klaas, J.E.; Schworm, B.; Kreutzer, T.C.; Priglinger, S.G.; Siedlecki, J. Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age-related macular degeneration. Sci. Rep. 2024, 14, 9600. [Google Scholar] [CrossRef] [PubMed]
- Liu, D.; Li, C.; Cui, L.; Li, S. Short-term comparison of switching to faricimab from other anti-VEGF agents in neovascular age-related macular degeneration patients: A retrospective study. Medicine 2025, 104, e42002. [Google Scholar] [CrossRef] [PubMed]
- Schneider, M.; Bjerager, J.; Hodzic-Hadzibegovic, D.; Klefter, O.N.; Subhi, Y.; Hajari, J. Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration. Graefe Arch. Clin. Exp. Ophthalmol. 2024, 262, 2153–2162. [Google Scholar] [CrossRef]
- Hunt, A.; Hashimoto, Y.; Young, S.; Arnold, J.; Game, J.; Hooper, C.; Field, A.; Barry, R.; Barthelmes, D.; Gillies, M. Outcomes after switching to faricimab in neovascular age-related macular degeneration: Data from the Fight Retinal Blindness! registry. Clin. Exp. Ophthalmol. 2025; ahead of print. [Google Scholar] [CrossRef]
- Takahashi, H.; Inoda, S.; Takahashi, H.; Takahashi, R.; Hashimoto, Y.; Yoshida, H.; Kawashima, H.; Yanagi, Y. One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment. Sci. Rep. 2024, 14, 9087. [Google Scholar] [CrossRef]
- Grimaldi, G.; Cancian, G.; Rizzato, A.; Casanova, A.; Perruchoud-Ader, K.; Clerici, M.; Consigli, A.; Menghini, M. Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: A real-world prospective study. Graefe Arch. Clin. Exp. Ophthalmol. 2023, 262, 1151–1159. [Google Scholar] [CrossRef]
- Heinke, A.; Warter, A.; Nagel, I.D.; Agnihotri, A.; Mehta, N.N.; Galang, C.M.B.; Deussen, D.N.; Bartsch, D.-U.G.; Cheng, L.; Ferreyra, H.A.; et al. Faricimab for treatment-resistant choroidal neovascularization (CNV) in neovascular age-related macular degeneration (nAMD): Seven-month results using artificial intelligence and OCTA. Int. J. Retin. Vitr. 2025, 11, 68. [Google Scholar] [CrossRef] [PubMed]
- Wolfrum, P.; Böhm, E.W.; Lorenz, K.; Stoffelns, B.; Pfeiffer, N.; Korb, C.A. Clinical outcomes following a switch of therapy to faricimab in patients affected by neovascular age-related macular degeneration. J. Clin. Med. 2025, 14, 423. [Google Scholar] [CrossRef] [PubMed]
- Gilligan, A.K.; Ramsey, D.J. Beyond longer intervals: Advocating for regular treatment of neovascular AMD. J. Clin. Med. 2024, 14, 57. [Google Scholar] [CrossRef] [PubMed]
Analyzed Trait | Values |
---|---|
No. of participants, n | 66 |
No. of eyes, n | 72 |
Gender, n (%) | Female: 33 (50.0%) |
Male: 33 (50.0%) | |
Age [y], M (SD) | 76.51 (6.56) |
MNV type, n (%) | Type 1: 62 (86.11%) |
Type 2: 1 (1.39%) | |
Type 3: 5 (6.94%) | |
Type 4: 4 (5.56%) | |
PCV, n (%) | 4 (5.56%) |
SRF, n (%) | 61 (84.72%) |
IRF, n (%) | 23 (31.94%) |
SHRM, n (%) | 9 (12.50%) |
Hemorrhage, n (%) | 4 (5.56%) |
PED, n (%) | 12 (16.67%) |
CST [µm], M (SD) | 266.19 (58.37) |
Visual acuity [logMAR], M (SD) | 0.25 (0.22) |
No. of injections before switching, M (SD) | 32.49 (19.29) |
Last interval duration [w], M (SD) | 5.67 (1.93) |
Treatment duration before switch [m], M (SD) | 52.89 (37.60) |
Overall treatment duration [m], M (SD) | 63.25 (38.10) |
Analyzed Condition | Baseline | Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | p-Value * |
---|---|---|---|---|---|---|---|---|
SRF | 60 (84.51%) | 23 (31.94%) | 20 (28.17%) | 21 (29.17%) | 37 (51.39%) | 35 (49.30%) | 37 (52.11%) | <0.0001 |
IRF | 23 (31.94%) | 9 (12.50%) | 9 (12.50%) | 9 (12.50%) | 20 (27.78%) | 22 (30.99%) | 20 (28.17%) | 0.3657 |
SHRM | 9 (12.50%) | 4 (5.56%) | 4 (5.56%) | 3 (4.17%) | 5 (6.94%) | 4 (5.63%) | 3 (4.22%) | 0.1317 |
Hemorrhage | 4 (5.56%) | 3 (4.17%) | 2 (2.78%) | 1 (1.39%) | 2 (2.78%) | 0 (0.00%) | 1 (1.41%) | 0.0833 |
PED | 12 (16.67%) | 9 (12.50%) | 8 (11.11%) | 9 (12.50%) | 9 (12.50%) | 8 (11.27%) | 8 (11.27%) | 0.0455 |
Visit | M | SD | Omnibus p Value | Paired p Value * |
---|---|---|---|---|
Baseline | 266.19 | 58.37 | 0.0006 | – |
1 | 231.65 | 57.28 | <0.0001 | |
2 | 231.17 | 45.88 | <0.0001 | |
3 | 233.29 | 50.73 | <0.0001 | |
4 | 257.90 | 56.38 | 0.3248 | |
5 | 254.90 | 54.47 | 0.0923 | |
6 | 261.35 | 55.41 | 0.3987 |
Visit | M | SD | Omnibus p Value | Paired p Value * |
---|---|---|---|---|
Baseline | 0.25 | 0.22 | 0.0002 | – |
1 | 0.24 | 0.20 | 0.2739 | |
2 | 0.23 | 0.24 | 0.1698 | |
3 | 0.22 | 0.20 | 0.0287 | |
4 | 0.24 | 0.20 | 0.5453 | |
5 | 0.27 | 0.25 | 0.3367 | |
6 | 0.28 | 0.24 | 0.1001 |
Visit | M | SD | p Value |
---|---|---|---|
Baseline | 5.67 | 1.93 | <0.0001 |
Final (6) post switch | 8.86 | 2.25 | – |
Delta | 3.07 | 2.43 | – |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kucharczuk, J.; Kasprzak, H.; Gawęcki, M. Switching from Aflibercept to Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration: Short-Term Results from Real-Life Study. J. Clin. Med. 2025, 14, 7345. https://doi.org/10.3390/jcm14207345
Kucharczuk J, Kasprzak H, Gawęcki M. Switching from Aflibercept to Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration: Short-Term Results from Real-Life Study. Journal of Clinical Medicine. 2025; 14(20):7345. https://doi.org/10.3390/jcm14207345
Chicago/Turabian StyleKucharczuk, Jan, Hubert Kasprzak, and Maciej Gawęcki. 2025. "Switching from Aflibercept to Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration: Short-Term Results from Real-Life Study" Journal of Clinical Medicine 14, no. 20: 7345. https://doi.org/10.3390/jcm14207345
APA StyleKucharczuk, J., Kasprzak, H., & Gawęcki, M. (2025). Switching from Aflibercept to Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration: Short-Term Results from Real-Life Study. Journal of Clinical Medicine, 14(20), 7345. https://doi.org/10.3390/jcm14207345